FDA warns of pancreatitis deaths from treatment with Allergan's IBS-D med Viberzi
Allergan has been working hard to buoy IBS-D med Viberzi through a series of marketing efforts and tech partnerships. But now, a safety hurdle could get in the way. The FDA has warned that patients without a gallbladder shouldn’t use the med after an agency review found an increased risk for those patients of developing serious pancreatitis that could result in hospitalization or even death.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063